PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 
iHealthcareAnalyst, Inc.

Press Release


Receive press releases from iHealthcareAnalyst, Inc.: By Email RSS Feeds:

Short Bowel Syndrome Diagnostics and Treatment Market by Test types, Drug Classes, Trends, and Forecast to 2021, Upcoming Report by iHealthcareAnalyst, Inc.


Short Bowel Syndrome Diagnostics and Treatment Market by Test Type (Complete Blood Test, Fecal Fat Test, Imaging Tests X-Ray, Ct Scan, Others), and Drug Class (GLP-2, Growth Hormone, L-Glutamine, Others) and Forecast 2017-2021

Maryland Heights, MO, May 04, 2017 --(PR.com)-- Short bowel syndrome (SBS) is a group of problems related to poor absorption of nutrients. Short bowel syndrome typically occurs in people who have had at least half of their small intestine removed and sometimes all or part of their large intestine removed, significant damage of the small intestine, poor motility, or movement, inside the intestines. diagnoses short bowel syndrome based on a medical and family history, a physical exam, blood tests, fecal fat tests, an x-ray of the small and large intestines, upper gastrointestinal (GI) series, computerized tomography (CT) scan, etc. Treatment will often include medications, and in some instances surgery. General medications to treat short bowel syndrome include antibiotics to prevent bacterial overgrowth, H2 blockers to treat too much gastric acid secretion, proton pump inhibitors to treat too much gastric acid secretion, choleretic agents to improve bile flow and prevent liver disease, bile-salt binders to decrease diarrhea, anti-secretin agents to reduce gastric acid in the intestine, hypomotility agents to increase the time it takes food to travel through the intestines, leading to increased nutrient absorption, growth hormones to improve intestinal absorption, teduglutide to improve intestinal absorption. Typically, the SBS treatment regime includes Teduglutide (Gattex) hormone, L-glutamine, or Somatropin (Zorbtive), a human growth hormone.

Browse Short Bowel Syndrome Diagnostics and Treatment Market by Test Type (Complete Blood Test, Fecal Fat Test, Imaging Tests – X-Ray, Ct Scan, Others), and Drug Class (GLP-2, Growth Hormone, L-Glutamine, Others) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/short-bowel-syndrome-diagnostics-treatment-market/

The global short bowel syndrome diagnostics and treatment market segmentation is based on test type (complete blood test, fecal fat test, imaging tests such as X-ray, CT scan, others) and drug class (GLP-2, growth hormones, and L-glutamine, others).

The global short bowel syndrome diagnostics and treatment market report provides market size (Revenue USD Million 2014 to 2021), market share and forecasts growth trends (CAGR%, 2017 to 2021). The global short bowel syndrome diagnostics and treatment market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global short bowel syndrome diagnostics and treatment market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market and provides analysis of the company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.

Major players operating in the global short bowel syndrome diagnostics and treatment market and included in this report are Ardelyx, Inc., Emmaus Life Sciences, Inc., GLyPharma Therapeutic, Inc., Merck KGaA, Naia Pharmaceuticals, Inc., Nutrinia Ltd., OxThera, Sancilio and Company, Inc., Shire plc, and Zealand Pharma A/S.

1. Test Type
1.1. Complete Blood Test
1.2. Fecal Fat Test
1.3. Imaging Tests
1.3.1. X-ray
1.3.2. CT Scan
1.4. Others

2. Drug Class
2.1. GLP-2
2.2. Growth Hormones
2.3. L-Glutamine
2.4. Others

3. Geography
3.1. North America (U.S., Canada)
3.2. Latin America (Brazil, Mexico, Rest of LA)
3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4. Asia Pacific (Japan, China, India, Rest of APAC)
3.5. Rest of the World

4. Company Profiles
4.1. Ardelyx, Inc.
4.2. Emmaus Life Sciences, Inc.
4.3. GLyPharma Therapeutic, Inc.
4.4. Merck KGaA
4.5. Naia Pharmaceuticals, Inc.
4.6. Nutrinia Ltd.
4.7. OxThera
4.8. Sancilio and Company, Inc.
4.9. Shire plc
4.10. Zealand Pharma A/S

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/short-bowel-syndrome-diagnostics-treatment-market/

About Us
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.

Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com

Website: https://www.ihealthcareanalyst.com
Contact Information
iHealthcareAnalyst, Inc.
Ana Aitawa
(314) 500-7508
Contact
https://www.ihealthcareanalyst.com/

Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc.
Promote Your Business